GlassScriptPhysician profile
Barinder S Athwal
NPI 1699762674
$5,087.08
in general payments reported to CMS, 2019-2025
34 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $586 · 2021: $827 · 2022: $882 · 2023: $647 · 2024: $923 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $696.93 | 2019-2024 | Veritas Vision System, Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $595.17 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $505.89 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Allergan, INC. | $392.58 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $343.20 | 2020-2022 | |
| New World Medical,INC. | $338.57 | 2022 | |
| Alcon Vision LLC | $294.80 | 2022-2025 | Rocklatan, Clareon, Simbrinza |
| Oyster Point Pharma, INC. | $244.86 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Biotissue Holdings INC. | $196.14 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $184.17 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $154.94 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $152.35 | 2019-2021 | |
| Rxsight INC | $134.16 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Abbvie INC. | $133.82 | 2022-2025 | Lumigan, Alphagan P |
| Sight Sciences, INC. | $119.53 | 2019-2023 | Omni Surgical System |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $87.61 | 2023-2024 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $85.82 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $55.43 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $47.75 | 2020-2024 | Ultomiris |
| Eyepoint US, INC. | $39.74 | 2019 | |
| Rayner Intraocular Lenses Limited | $35.37 | 2022-2024 | Rayone Spheric, Omidria, Rayone Aspheric |
| Harrow Eye, LLC | $34.02 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $24.89 | 2019-2022 | |
| Ivantis, INC | $21.03 | 2019 | |
| Topcon Healthcare, INC. | $20.68 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Iridex Corporation | $18.17 | 2019 | |
| Ani Pharmaceuticals, INC. | $17.74 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $17.63 | 2025 | Tepezza |
| Astellas Pharma US INC | $17.32 | 2023 | Izervay |
| Dompe US, INC. | $17.16 | 2024 | Oxervate |
| Ocular Therapeutix, INC. | $14.99 | 2022 | |
| Omeros Corporation | $12.88 | 2020 | |
| Genentech USA, INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barinder Athwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.